|Bid||0.00 x 3000|
|Ask||6.44 x 800|
|Day's Range||6.23 - 6.34|
|52 Week Range||5.57 - 10.60|
|Beta (5Y Monthly)||1.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.33|
American Renal Associates Holdings, Inc. (NYSE: ARA) (the "Company"), a leading provider of outpatient dialysis services, is pleased to announce that the Company has received preliminary approval of the settlement of a stockholder derivative action brought by Plaintiff Luke Johnson, and pending in the United States District Court for the District of New Jersey (case number No. 19-cv-15812) (the "Johnson Action"). The proposed settlement releases all claims asserted against the Company and the other named defendants in the Johnson Action without any liability or wrongdoing attributed to them. The proposed settlement remains subject to court approval and other customary conditions.
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
American Renal Associates Holdings, Inc. (NYSE: ARA) (the "Company"), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and operating results for the second quarter ended June 30, 2020. The Company also provided an update on its COVID-19 impact and affirmed its 2020 Adjusted EBITDA less noncontrolling interests ("Adjusted EBITDA-NCI") Outlook. These updates are highlighted later in this release.